Docetaxel-induced acute myositis: a case report with review of literature.

Abstract

Docetaxel is an anti-microtubule agent and a highly effective treatment of locally advanced and metastatic breast cancer. There are several adverse effects associated with docetaxel, such as myelosuppression, peripheral neuropathy, fluid retention, and asthenia. One of the most well-known side-effects of this medication is mild to moderate myalgia. Here, we report a case of a 49-year-old female with stage 3 breast cancers who developed severe acute myositis following docetaxel use. The mechanism of docetaxel-induced myositis remains unclear; however, physicians still need to be aware of the possibility of this complication in patients with cancer and a history of exposure to this medication.

• Authors: Sariya Wongsaengsak, Miguel Quirch, Somedeb Ball, Anita Sultan, Nusrat Jahan, Mohamed Elmassry, Shabnam Rehman
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 33 Issue 2 Pg. 116-121 (Apr 2021) ISSN: 1973-9478 [Electronic] England
• PMID: 32619151 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Docetaxel

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy)
• Docetaxel (adverse effects, therapeutic use)
• Female
• Humans
• Middle Aged
• Myositis (chemically induced)